ARCHIVES

Zytiga and Prednisone Extends Overall Survival in mCRPC Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

FDA, NCI Remain At Odds Over Drug approval Guidelines Despite Reconciliation Discussion

October 9, 1987

Former DCRRC Chief Saunders Proposes Total Separation Of NCI Intramural, Extramural Research

February 10, 1978

“Bring Contracts Under Control, Save $100,00 A Year,” Samuels Tells NCI

November 2, 1979

UT System (Again) Directs DePinho to Cure MD Anderson Faculty Angst

November 7, 2014

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

March 29, 2013

Two OAM Advisors Criticize Third over ACS Membership

July 23, 1993